AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Up 248.8% in November

AstraZeneca PLC (OTCMKTS:AZNCF) was the target of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 147,200 shares, a growth of 248.8% from the October 31st total of 42,200 shares. Based on an average daily volume of 3,800 shares, the days-to-cover ratio is currently 38.7 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in AstraZeneca stock. Kennedy Capital Management LLC acquired a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 37,554 shares of the company’s stock, valued at approximately $5,068,000. 40.87% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

AstraZeneca stock traded up $3.34 during midday trading on Thursday, reaching $134.70. The stock had a trading volume of 791 shares, compared to its average volume of 2,655. The company has a fifty day moving average price of $143.89 and a two-hundred day moving average price of $154.12. AstraZeneca has a 12 month low of $118.16 and a 12 month high of $175.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.